CompanyGraph
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- PositionReturn on equity is 24.2%, higher than 95% of its Medical Instruments & Supplies peers (median 5.6%)
- FinancialsAltman Z-Score 11.51: safe zone
- Interpretations9 currently firing — 9
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.67%Above 5Y avg (2.63%)
Annual Rate
GBP 0.11Paid semi-annual
Payout Ratio
87.4%High
Payback Period
29.9 yr
Last Ex-Dividend
Mar 19, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
204.31MGBP278.95M · vs all stocks (USD)
Trailing P/E
26.56xvs Medical Instruments & Supplies peers
Revenue (TTM)
49.54MGBP67.63M · vs all stocks (USD)
Profit Margin
15.88%vs Medical Instruments & Supplies peers
Beta
0.3460xvs all stocks
52-Week Change
18.06%vs all stocks
Forward Annual Dividend Yield
2.67%vs all stocks
Market Capitalization
204.31MGBP278.95M · vs all stocks (USD)
Enterprise Value
194.25MGBP265.22M · vs all stocks (USD)
Trailing P/E
26.56xvs Medical Instruments & Supplies peers
Forward P/E
20.79xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
4.12xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
6.05xvs Medical Instruments & Supplies peers
Enterprise to Revenue
3.92xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
16.96xvs Medical Instruments & Supplies peers
Profit Margin
15.88%vs Medical Instruments & Supplies peers
Operating Margin
19.71%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
14.46%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
24.19%vs Medical Instruments & Supplies peers
Revenue (TTM)
49.54MGBP67.63M · vs all stocks (USD)
Revenue per Share (TTM)
1.04GBPUpdated Aug 22, 2026Quarterly Revenue Growth
13.60%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
40.45MGBP55.23M · vs all stocks (USD)
EBITDA (TTM)
12.83MGBP17.52M · vs all stocks (USD)
Net Income (TTM)
7.86MGBP10.74M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
44.80%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
10.45MGBP14.27M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
7.08MGBP9.67M · vs all stocks (USD)
Forward Annual Dividend Rate
0.1136GBPUpdated Aug 22, 2026Forward Annual Dividend Yield
2.67%vs all stocks
Trailing Annual Dividend Rate
0.1420GBPUpdated Aug 22, 2026Trailing Annual Dividend Yield
3.34%vs all stocks
5-Year Average Dividend Yield
2.63%vs all stocks
Payout Ratio
87.44%vs Medical Instruments & Supplies peers
Revenue
46.46MGBPFY2025 · Jun 30, 2025Cost of Goods Sold
9.00MGBPFY2025 · Jun 30, 2025Gross Profit
37.46MGBPFY2025 · Jun 30, 2025Operating Income
9.76MGBP13.32M · vs all stocks (USD)
Pre-tax Income
8.42MGBPFY2025 · Jun 30, 2025Income Tax Expense
1.78MGBPFY2025 · Jun 30, 2025Net Income
6.64MGBPFY2025 · Jun 30, 2025EBIT
8.68MGBPFY2025 · Jun 30, 2025EBITDA (Income Statement)
12.83MGBPFY2025 · Jun 30, 2025Selling, General & Administrative
24.95MGBPFY2025 · Jun 30, 2025Non-operating Interest Income
278.00KGBPFY2025 · Jun 30, 2025Non-operating Interest Expense
259.00KGBPFY2025 · Jun 30, 2025Preferred Stock Dividends
0.00GBPFY2025 · Jun 30, 2025Operating Cash Flow
7.87MGBPFY2025 · Jun 30, 2025Free Cash Flow
7.01MGBPFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
8.64MGBPFY2025 · Jun 30, 2025Starting Profit (CF Statement)
8.42MGBPFY2025 · Jun 30, 2025Stock-based Compensation
371.00KGBPFY2025 · Jun 30, 2025Other Non-cash Items
-19.00KGBPFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
-939.00KGBPFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
39.00KGBPFY2025 · Jun 30, 2025Capital Expenditures
-857.00KGBPFY2025 · Jun 30, 2025Net Intangibles (CF)
-1.13MGBPFY2025 · Jun 30, 2025Purchase of Investments
-11.20MGBPFY2025 · Jun 30, 2025Sale of Investments
12.65MGBPFY2025 · Jun 30, 2025Net Investing Cash Flow
593.00KGBPFY2025 · Jun 30, 2025Common Dividends Paid
-6.66MGBPFY2025 · Jun 30, 2025Net Financing Cash Flow
-6.28MGBPFY2025 · Jun 30, 2025Shares Outstanding
47.85MSharesUpdated Aug 22, 2026Float Shares
46.07MSharesUpdated Aug 22, 2026% Held by Insiders
2.36%vs all stocks
% Held by Institutions
49.41%vs all stocks
Total Cash (MRQ)
13.29MGBP18.14M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2780GBPUpdated Aug 22, 2026Total Debt (MRQ)
5.82MGBP7.95M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1736xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
4.13xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
0.7030GBPUpdated Aug 22, 2026Total Assets
45.33MGBP61.89M · vs all stocks (USD)
Total Current Assets
26.18MGBPFY2025 · Jun 30, 2025Total Liabilities
12.34MGBPFY2025 · Jun 30, 2025Total Non-current Assets
19.16MGBPFY2025 · Jun 30, 2025Total Non-current Liabilities
5.08MGBPFY2025 · Jun 30, 2025Total Current Liabilities
7.26MGBPFY2025 · Jun 30, 2025Cash
8.64MGBPFY2025 · Jun 30, 2025Cash & Cash Equivalents
8.64MGBPFY2025 · Jun 30, 2025Other Short-term Investments
4.20MGBPFY2025 · Jun 30, 2025Accounts Receivable
6.43MGBPFY2025 · Jun 30, 2025Inventory
4.64MGBPFY2025 · Jun 30, 2025Accounts Payable
1.59MGBPFY2025 · Jun 30, 2025Short-term Debt
1.14MGBPFY2025 · Jun 30, 2025Long-term Debt
4.74MGBPFY2025 · Jun 30, 2025Common Stock (Book)
478.00KGBPFY2025 · Jun 30, 2025Retained Earnings
15.80MGBPFY2025 · Jun 30, 2025Total Shareholders' Equity
32.99MGBP45.04M · vs all stocks (USD)
52-Week Low
350.00GBXUpdated Aug 22, 202652-Week High
450.00GBXUpdated Aug 22, 202652-Week Change
18.06%vs all stocks
Beta
0.3460xvs all stocks
50-Day MA
401.31GBXUpdated Aug 22, 2026200-Day MA
394.93GBXUpdated Aug 22, 2026Avg 10-Day Volume
114.67KSharesUpdated Aug 22, 2026Avg 30-Day Volume
133.55KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
0.1600GBPUpdated Aug 22, 20269 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 24.2%, higher than 95% of its Medical Instruments & Supplies peers (median 5.6%)Significant
Return on equity: 0.24Industry median: 0.06Industry P95: 0.21Peers compared: 65.00
Return on assets is 14.5%, higher than 95% of its Medical Instruments & Supplies peers (median 4%)Significant
Return on assets: 0.14Industry median: 0.04Industry P95: 0.13Peers compared: 65.00
Financial Health
Altman Z-Score 11.51: safe zoneNotable
Altman Z-Score: 11.51
High earnings qualityNotable
Earnings Quality Score: 0.58
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Companies that share the same coordination system — how they create, deliver, or capture value.
NOCIL Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Airjoule Technologies Corp.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Iljin Hysolus Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Hangzhou iEcho Science & Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Sichuan Golden Summit Group Joint-stock Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Jiangsu Hongde Special Parts Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Young Optics Inc.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Zhejiang Linuo Flow Control Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Compucase Enterprise Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Tangshan Jidong Equipment Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Catalyst Pharmaceuticals Inc.
9 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
NVIDIA Corporation
9 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
ResMed Inc.
9 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin